Fig. 3From: Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2bA. Top2b level in PBMCs 48 h following dexrazoxane infusionBack to article page
